AU2009262871B2 - Stabilized transdermal drug delivery system - Google Patents

Stabilized transdermal drug delivery system Download PDF

Info

Publication number
AU2009262871B2
AU2009262871B2 AU2009262871A AU2009262871A AU2009262871B2 AU 2009262871 B2 AU2009262871 B2 AU 2009262871B2 AU 2009262871 A AU2009262871 A AU 2009262871A AU 2009262871 A AU2009262871 A AU 2009262871A AU 2009262871 B2 AU2009262871 B2 AU 2009262871B2
Authority
AU
Australia
Prior art keywords
adhesive
therapeutic agent
solution
drug delivery
release liner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009262871A
Other languages
English (en)
Other versions
AU2009262871A1 (en
Inventor
Jiashang Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41380695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009262871(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of AU2009262871A1 publication Critical patent/AU2009262871A1/en
Assigned to MYLAN INC. reassignment MYLAN INC. Amend patent request/document other than specification (104) Assignors: MYLAN LABORATORIES, INC.
Priority to AU2016202212A priority Critical patent/AU2016202212B2/en
Application granted granted Critical
Publication of AU2009262871B2 publication Critical patent/AU2009262871B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009262871A 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system Active AU2009262871B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202212A AU2016202212B2 (en) 2008-05-30 2016-04-08 Stabilized transdermal drug delivery system

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5745508P 2008-05-30 2008-05-30
US61/057,455 2008-05-30
PCT/US2009/045739 WO2009158120A2 (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202212A Division AU2016202212B2 (en) 2008-05-30 2016-04-08 Stabilized transdermal drug delivery system

Publications (2)

Publication Number Publication Date
AU2009262871A1 AU2009262871A1 (en) 2009-12-30
AU2009262871B2 true AU2009262871B2 (en) 2016-04-14

Family

ID=41380695

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009262871A Active AU2009262871B2 (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system
AU2016202212A Active AU2016202212B2 (en) 2008-05-30 2016-04-08 Stabilized transdermal drug delivery system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016202212A Active AU2016202212B2 (en) 2008-05-30 2016-04-08 Stabilized transdermal drug delivery system

Country Status (11)

Country Link
US (2) US20110182949A1 (https=)
EP (1) EP2299989B1 (https=)
JP (2) JP5695562B2 (https=)
KR (1) KR101590209B1 (https=)
CN (1) CN102099020B (https=)
AU (2) AU2009262871B2 (https=)
BR (1) BRPI0913214B1 (https=)
CA (1) CA2726136C (https=)
MX (1) MX2010012989A (https=)
NZ (1) NZ589542A (https=)
WO (1) WO2009158120A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
CN102630160B (zh) * 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
US9925150B2 (en) * 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US20150196515A1 (en) * 2012-08-15 2015-07-16 Dow Coming Corporation Multi-Layer Drug Delivery System
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) * 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145502B1 (en) * 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
CA2962080A1 (en) 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
KR102241892B1 (ko) 2017-01-25 2021-04-20 한국전자기술연구원 백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치
TWI741168B (zh) * 2017-04-28 2021-10-01 日商日東電工股份有限公司 經皮吸收製劑
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN113453676B (zh) * 2019-02-15 2025-08-05 久光制药株式会社 罗替戈汀稳定化方法
CN113677343B (zh) * 2019-03-19 2023-11-24 耐贝医药株式会社 生物体对药物的吸收性优异且化学稳定性也优异的医药组合物
JP2022535003A (ja) * 2019-05-31 2022-08-04 キンデーバ ドラッグ デリバリー リミティド パートナーシップ 接着促進剤を特徴とする除去可能なフィルム形成ゲル組成物
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
CN115989025A (zh) * 2020-08-31 2023-04-18 耐贝医药株式会社 用于缓解或治疗神经退行性疾病的症状的贴剂
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
KR102363479B1 (ko) * 2021-03-12 2022-02-15 환인제약 주식회사 로티고틴 함유 경피 흡수 제제
JP2024520271A (ja) * 2021-06-06 2024-05-24 スタートン セラピューティクス インコーポレイテッド 治療上有効な量のレナリドミドまたは他の免疫調節剤を投与するための経皮薬物送達システム
CN116270575A (zh) * 2021-08-16 2023-06-23 乐明药业(苏州)有限公司 一种含有氟比洛芬的药物组合物与贴剂
CN120417892A (zh) * 2022-12-26 2025-08-01 丸仁制药株式会社 透皮吸收制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19906152A1 (de) * 1999-02-10 2000-08-17 Jenapharm Gmbh Wirkstoffhaltige Laminate für Transdermalsysteme
US20060099242A1 (en) * 1994-09-14 2006-05-11 Garbe James E Matrix for transdermal drug delivery
EP1671626A1 (de) * 2004-12-20 2006-06-21 Schering Aktiengesellschaft Transdermales Pflaster mit Progesteron A-spezifischen Liganden (PRASL) als Wirkstoff
WO2008115371A2 (en) * 2007-03-16 2008-09-25 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
JPS60169414A (ja) * 1984-02-14 1985-09-02 Taisho Pharmaceut Co Ltd 経皮吸収剤
US4797284A (en) 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
US5662928A (en) 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
KR970009795A (ko) * 1995-08-30 1997-03-27 이웅열 경피투여용 첩부제 조성물
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
ATE207348T1 (de) * 1995-12-01 2001-11-15 Alza Corp Verbessertes verfahren zur verhinderung der kristallbildung in einer dispersion eines flüssigen stoffes in einer matrix
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) * 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
KR100682729B1 (ko) * 2004-06-15 2007-02-15 (주)아모레퍼시픽 신규 경피흡수제제 및 그 제조방법
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
WO2007077741A1 (ja) * 2005-12-28 2007-07-12 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収型製剤
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
RU2013139701A (ru) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US20060099242A1 (en) * 1994-09-14 2006-05-11 Garbe James E Matrix for transdermal drug delivery
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19906152A1 (de) * 1999-02-10 2000-08-17 Jenapharm Gmbh Wirkstoffhaltige Laminate für Transdermalsysteme
EP1671626A1 (de) * 2004-12-20 2006-06-21 Schering Aktiengesellschaft Transdermales Pflaster mit Progesteron A-spezifischen Liganden (PRASL) als Wirkstoff
WO2008115371A2 (en) * 2007-03-16 2008-09-25 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization

Also Published As

Publication number Publication date
JP5695562B2 (ja) 2015-04-08
BRPI0913214A2 (pt) 2016-01-19
AU2009262871A1 (en) 2009-12-30
CA2726136A1 (en) 2009-12-30
NZ589542A (en) 2012-10-26
MX2010012989A (es) 2011-04-27
US9226902B2 (en) 2016-01-05
CN102099020B (zh) 2013-09-18
JP2015083569A (ja) 2015-04-30
AU2016202212B2 (en) 2018-05-10
EP2299989B1 (en) 2019-01-02
US20090299304A1 (en) 2009-12-03
US20110182949A1 (en) 2011-07-28
AU2016202212A1 (en) 2016-05-12
KR20110025931A (ko) 2011-03-14
KR101590209B1 (ko) 2016-02-01
CN102099020A (zh) 2011-06-15
JP2011521974A (ja) 2011-07-28
WO2009158120A2 (en) 2009-12-30
EP2299989A2 (en) 2011-03-30
BRPI0913214B1 (pt) 2022-05-17
CA2726136C (en) 2016-11-01
WO2009158120A3 (en) 2010-03-04
EP2299989A4 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
AU2009262871B2 (en) Stabilized transdermal drug delivery system
AU2009302853B2 (en) Amorphous rotigotine transdermal system
Banerjee et al. Aspect of adhesives in transdermal drug delivery systems
US7556823B2 (en) Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
US10532033B2 (en) Microreservoir system based on polysiloxanes and ambiphilic solvents
EP2190392A1 (en) Transdermal drug delivery systems comprising a coated release liner
JP2003511425A (ja) 二元粘着性経皮薬物デリバリーシステム
WO2009119672A1 (ja) β遮断剤の安定化組成物およびそれを用いた経皮吸収製剤
US20180235903A1 (en) Fentanyl Transdermal Delivery System
CN118159255A (zh) 具有柔性背衬的闭塞性贴剂
KR20250100074A (ko) 테트라하이드로칸나비놀을 유효성분으로 포함하는 경피흡수 패치제
EP3086783B1 (en) Compositions and methods for transdermal delivery of amphetamine
HK1197883A (en) Amorphous rotigotine transdermal system
CN101304735A (zh) 用于挥发性和/或热不稳定的物质的经皮治疗体系
HK1075816B (en) Transdermal delivery of fentanyl

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)